Skip to main content
. 2024 Nov 30;67(23):21486–21504. doi: 10.1021/acs.jmedchem.4c02366

Figure 7.

Figure 7

SHO1122147 decreases liver steatosis and lowers ALT in a mouse model of NASH. (A) Liver weight and (B) plasma alanine aminotransferase (ALT) activity levels. (C) Liver triglycerides (TG) at the end of the study. (D–F) Individual and (G) composite NAFLD activity scores. (H) Liver fibrosis stage. Values are represented as mean ± SEM (n = 4–5). *p < 0.05 compared with GAN, determined by (C) unpaired parametric t test (two-tailed) and (B, G) Mann–Whitney nonparametric test.